Science Explorer Back to mapMap

Most cited papers from International Tuberculosis Research Center

International Tuberculosis Research Center

What are the most cited papers from International Tuberculosis Research Center?

The most cited paper from International Tuberculosis Research Center is "Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics" (Eskild Petersen, Marion Koopmans, Unyeong Yu Go et al., 2020), with 1,295 citations. Next come "Tuberculous Granulomas Are Hypoxic in Guinea Pigs, Rabbits, and Nonhuman Primates" (666) and "Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis" (648).

Showing 50 of 60 papers. Every paper with more than 40 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics Eskild Petersen, Marion Koopmans, Unyeong Yu Go et al. · The Lancet Infectious Diseases Open access 3 Jul 2020 1,295
2 Tuberculous Granulomas Are Hypoxic in Guinea Pigs, Rabbits, and Nonhuman Primates Laura E. Via, Philana Ling Lin, Sonja M. Ray et al. · Infection and Immunity Open access 17 Mar 2008 666
3 Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis Nafees Ahmad et al. · The Lancet ReviewOpen access108 authors Sep 2018 648
4 Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis Myungsun Lee et al. · New England Journal of Medicine Open access 18 Oct 2012 565
5 Neutrophils Are the Predominant Infected Phagocytic Cells in the Airways of Patients With Active Pulmonary TB Seok-Yong Eum, Ji-Hye Kong, Min-Sun Hong et al. · CHEST Journal Open access 12 Sep 2009 556
6 Pyrazinamide Inhibits Trans-Translation in Mycobacterium tuberculosis Wanliang Shi, Xuelian Zhang, Xin Jiang et al. · Science Open access 12 Aug 2011 522
7 The association between sterilizing activity and drug distribution into tuberculosis lesions Brendan Prideaux, Laura E. Via, Matthew D. Zimmerman et al. · Nature Medicine Open access 7 Sep 2015 486
8 Microenvironments in Tuberculous Granulomas Are Delineated by Distinct Populations of Macrophage Subsets and Expression of Nitric Oxide Synthase and Arginase Isoforms Joshua T. Mattila, Olabisi Olaniyi Ojo, Diane Kepka‐Lenhart et al. · The Journal of Immunology Open access 7 Jun 2013 359
9 High Content Screening Identifies Decaprenyl-Phosphoribose 2′ Epimerase as a Target for Intracellular Antimycobacterial Inhibitors Thierry Christophe et al. · PLoS Pathogens Open access 29 Oct 2009 337
10 Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure Stephanus T. Malherbe et al. · Nature Medicine Open access 5 Sep 2016 317
11 Inflammatory signaling in human tuberculosis granulomas is spatially organized Mohlopheni Jackson Marakalala, Ravikiran M. Raju, Kirti Sharma et al. · Nature Medicine Open access 4 Apr 2016 315
12 Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance Abigail L. Manson et al. · Nature Genetics Open access 16 Jan 2017 304
13 Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study Tracy L. Dalton, Peter Cegielski, Somsak Akksilp et al. · The Lancet Open access 29 Aug 2012 228
14 WHO global research priorities for antimicrobial resistance in human health Silvia Bertagnolio et al. · The Lancet Microbe Open access284 authors 13 Aug 2024 217
15 Tuberculosis drugs’ distribution and emergence of resistance in patient’s lung lesions: A mechanistic model and tool for regimen and dose optimization Natasha Strydom, Sneha V. Gupta, William S. Fox et al. · PLoS Medicine Open access 2 Apr 2019 207
16 Treatment Outcomes and Long-term Survival in Patients with Extensively Drug-resistant Tuberculosis Doh Hyung Kim, Hee Jin Kim, Seung-Kyu Park et al. · American Journal of Respiratory and Critical Care Medicine Open access 14 Aug 2008 186
17 PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis Ray Y. Chen et al. · Science Translational Medicine Open access 3 Dec 2014 162
18 High Persister Mutants in Mycobacterium tuberculosis Heather L. Torrey, Iris Keren, Laura E. Via et al. · PLoS ONE Open access 13 May 2016 161
19 Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa: a mathematical modelling study Aditya Sharma et al. · The Lancet Infectious Diseases Open access 9 May 2017 155
20 Extensive Drug Resistance Acquired During Treatment of Multidrug-Resistant Tuberculosis J. Peter Cegielski et al. · Clinical Infectious Diseases Open access 23 Jul 2014 150
21 Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis Yingda L. Xie et al. · New England Journal of Medicine Open access 13 Sep 2017 147
22 Mutations in gidB Confer Low-Level Streptomycin Resistance in Mycobacterium tuberculosis Sharon Y. Wong, Jong Seok Lee, Hyun-Kyung Kwak et al. · Antimicrobial Agents and Chemotherapy Open access 29 Mar 2011 144
23 Linezolid Trough Concentrations Correlate with Mitochondrial Toxicity-Related Adverse Events in the Treatment of Chronic Extensively Drug-Resistant Tuberculosis Taeksun Song, Myungsun Lee, Han-Seung Jeon et al. · EBioMedicine Open access 15 Oct 2015 143
24 PET/CT imaging reveals a therapeutic response to oxazolidinones in macaques and humans with tuberculosis M. Teresa Coleman, Ray Y. Chen, Myungsun Lee et al. · Science Translational Medicine Open access 3 Dec 2014 137
25 Differential Virulence and Disease Progression following Mycobacterium tuberculosis Complex Infection of the Common Marmoset (Callithrix jacchus) Laura E. Via et al. · Infection and Immunity Open access 29 May 2013 128
26 Transient drug-tolerance and permanent drug-resistance rely on the trehalose-catalytic shift in Mycobacterium tuberculosis Jae Jin Lee, Sun‐Kyung Lee, Naomi Song et al. · Nature Communications Open access 2 Jul 2019 126
27 Rufomycin Targets ClpC1 Proteolysis in Mycobacterium tuberculosis and M. abscessus Mary P Choules et al. · Antimicrobial Agents and Chemotherapy Open access 3 Jan 2019 124
28 Common Variants in the Glycerol Kinase Gene Reduce Tuberculosis Drug Efficacy Michelle M. Bellerose, Seung-Hun Baek, Chuan‐Chin Huang et al. · mBio Open access 29 Jul 2019 122
29 Sensititre MYCOTB MIC Plate for Testing Mycobacterium tuberculosis Susceptibility to First- and Second-Line Drugs Jongseok Lee, Derek T. Armstrong, Willy Ssengooba et al. · Antimicrobial Agents and Chemotherapy Open access 7 Oct 2013 110
30 Proteomic analysis of extracellular vesicles derived from Mycobacterium tuberculosis Jae‐Wook Lee, Si‐Hyun Kim, Dongsic Choi et al. · PROTEOMICS 23 Jul 2015 107
31 COVID-19–We urgently need to start developing an exit strategy Eskild Petersen, Sean A Wasserman, Shui Shan Lee et al. · International Journal of Infectious Diseases Open access 28 Apr 2020 101
32 Extensively Drug-Resistant Tuberculosis in South Korea: Risk Factors and Treatment Outcomes among Patients at a Tertiary Referral Hospital Christie Y. Jeon, Sung‐Hee Hwang, Jin Hong Min et al. · Clinical Infectious Diseases Open access 26 Dec 2007 101
33 Fitness costs of rifampicin resistance in M ycobacterium tuberculosis are amplified under conditions of nutrient starvation and compensated by mutation in the β′ subunit of RNA polymerase Taeksun Song et al. · Molecular Microbiology Open access 14 Jan 2014 99
34 Impact of Diabetes and Smoking on Mortality in Tuberculosis George W Reed, Hongjo Choi, So Young Lee et al. · PLoS ONE Open access 28 Feb 2013 93
35 Rapid detection of Mycobacterium tuberculosis biomarkers in a sandwich immunoassay format using a waveguide-based optical biosensor Harshini Mukundan, Sandeep Kumar, Dominique N. Price et al. · Tuberculosis Open access 18 Jun 2012 92
36 Efficacy and Safety of Metronidazole for Pulmonary Multidrug-Resistant Tuberculosis Matthew W. Carroll et al. · Antimicrobial Agents and Chemotherapy Open access 4 Jun 2013 83
37 Identification of serum biomarkers for active pulmonary tuberculosis using a targeted metabolomics approach Yonggeun Cho, Youngmok Park, Bora Sim et al. · Scientific Reports Open access 2 Mar 2020 77
38 Linezolid for XDR-TB — Final Study Outcomes Myungsun Lee, Taeksun Song, Youngran Kim et al. · New England Journal of Medicine Open access 15 Jul 2015 77
39 Host-Mediated Bioactivation of Pyrazinamide: Implications for Efficacy, Resistance, and Therapeutic Alternatives Laura E. Via et al. · ACS Infectious Diseases Open access 17 Mar 2015 77
40 Genetic Diversity of Mycobacterium tuberculosis Isolates from a Tertiary Care Tuberculosis Hospital in South Korea Isdore Chola Shamputa, Jongseok Lee, Caroline Allix‐Béguec et al. · Journal of Clinical Microbiology Open access 17 Dec 2009 75
41 Predictors of pulmonary tuberculosis treatment outcomes in South Korea: a prospective cohort study, 2005-2012 Hongjo Choi, Myungsun Lee, Ray Y. Chen et al. · BMC Infectious Diseases Open access 2 Jul 2014 74
42 Polymorphisms Associated with Resistance and Cross-Resistance to Aminoglycosides and Capreomycin in Mycobacterium tuberculosis Isolates from South Korean Patients with Drug-Resistant Tuberculosis Laura E. Via et al. · Journal of Clinical Microbiology Open access 24 Dec 2009 73
43 Mycolic acids as diagnostic markers for tuberculosis case detection in humans and drug efficacy in mice Guanghou Shui, Anne K. Bendt, Ignasius Aditya Jappar et al. · EMBO Molecular Medicine Open access 7 Dec 2011 69
44 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea Jeongha Mok et al. · The Lancet Open access Oct 2022 68
45 Latent Tuberculosis: Two Centuries of Confusion. Marcel A. Behr, Eva Kaufmann, Jacalyn M. Duffin et al. · Apollo (University of Cambridge) Open access 25 Jun 2021 65
46 Frequency of adverse reactions to first- and second-line anti-tuberculosis chemotherapy in a Korean cohort Miles W. Carroll et al. · The International Journal of Tuberculosis and Lung Disease Open access 14 May 2012 64
47 Natural killer cells are recruited during pulmonary tuberculosis and theirex vivoresponses to mycobacteria vary between healthy human donors in association with KIR haplotype Damien Portevin, Laura E. Via, Seok‐Yong Eum et al. · Cellular Microbiology Open access 13 Jul 2012 64
48 Detection of Isoniazid-, Fluoroquinolone-, Amikacin-, and Kanamycin-Resistant Tuberculosis in an Automated, Multiplexed 10-Color Assay Suitable for Point-of-Care Use Soumitesh Chakravorty et al. · Journal of Clinical Microbiology Open access 3 Nov 2016 58
49 Rapid Detection of Fluoroquinolone-Resistant and Heteroresistant Mycobacterium tuberculosis by Use of Sloppy Molecular Beacons and Dual Melting-Temperature Codes in a Real-Time PCR Assay Soumitesh Chakravorty, Bola Aladegbami, Kimberley Thoms et al. · Journal of Clinical Microbiology Open access 30 Dec 2010 57
50 Exploring Alternative Biomaterials for Diagnosis of Pulmonary Tuberculosis in HIV-Negative Patients by Use of the GeneXpert MTB/RIF Assay Shubhada Shenai, Danielle Amisano, Katharina Ronacher et al. · Journal of Clinical Microbiology Open access 10 Oct 2013 57

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.